FAIRFIELD, N.J., April 24 /PRNewswire-FirstCall/ -- Bradley Pharmaceuticals, Inc. today announced that it will participate in the UBS Global Specialty Pharmaceuticals Conference, April 24-25, 2006 at the Grand Hyatt New York in New York City.
Daniel Glassman, President and CEO, is scheduled to present on Tuesday, April 25, 2006 beginning at 4 p.m. (ET). Mr. Glassman will discuss the Company’s financial and business performance.
A live audio webcast of Mr. Glassman’s presentation can be accessed by visiting http://event.streamx.us/event/20060424, or http://www.bradpharm.com and clicking on Investor Relations, then Calendar of Events.
Please visit Bradley Pharmaceuticals web site at: http://www.bradpharm.com
Bradley Pharmaceuticals common stock is listed on the NYSE under the symbol BDY.
Bradley Pharmaceuticals, Inc. was founded in 1985 as a specialty pharmaceutical company and markets to niche physician specialties in the U.S. and 38 international markets. Bradley’s success is based on the strategy of Acquire, Enhance and Grow. Bradley Acquires non-strategic brands, Enhances these brands with line extensions and improved formulations and Grows the products through promotion, advertising and selling activities to optimize life cycle management. Bradley Pharmaceuticals is comprised of Doak Dermatologics, specializing in topical therapies for dermatology and podiatry; Kenwood Therapeutics, providing gastroenterology, respiratory and other internal medicine brands; and A. Aarons, which will market authorized generic versions of Doak and Kenwood therapies.
Important announcement:
Daniel Glassman will present at the Banc of America Securities LLC, Health Care Conference 2006, to be held at The Four Seasons Hotel in Las Vegas, NV, May 16, 2006 at 4 p.m.
Daniel Glassman will present a case study on Optimizing Lifecycle Management for a Product with Limited Patent Protection at the MedAd News’ Specialty Pharmaceuticals Summit, June 8, 2006 at 8:45 a.m. at the Park Hyatt, Philadelphia, PA.
Bradley Pharmaceuticals, Inc.
CONTACT: Anthony Griffo, Investor Relations, Bradley Pharmaceuticals,Inc., +1-973-882-1505, ext. 313
Web site: http://www.bradpharm.com/
